Summary. In three groups of normal subjects and in one group of patients with latent diabetes mellitus a study has been made of the effects of chlorpromazine (CPZ) on blood glucose and plasma insulin. CPZ 75 mg/day for 7 days did not alter the plasma insulin response after oral glucose; nor did CPZ 50 mg/day for 7 days affect the glucose assimilation rate or insulin response to glucose injection. Infusion of CPZ 50 mg in 60 min slightly increased the basal blood glucose level but had no significant effect on basal plasma insulin. The insulin/glucose ratio after the end of the infusion was significantly higher than during the period of infusion of the drug. In latent diabetic patients CPZ infusion significantly diminished the insulin/glucose ratio during an intravenous glucose tolerance test. These results suggest that, whereas prolonged treatment with low doses of CPZ did not modify glucose tolerance and glucose-stimulated pancreatic response, higher acute doses of the drug may induce hyperglycaemia and can inhibit insulin secretion both in normal man and in patients with latent diabetes mellitus.
and Scandellari et al. (1975) reported that administration of CPZ increased the level of blood glucose and inhibited insulin secretion in hypoglycaemic patients.
At present, the effect of CPZ on insulin secretion in normal man is not fully understood. The present study was done to examine the changes in blood glucose and plasma insulin produced by acute and shortterm administration of this drug.
Materials and Methods
Four types of experiments were performed in which three groups of healthy volunteers were studied after an overnight fast.
a. Experiment 1
An oral glucose tolerance test (IVGTI') was performed in five subjects. The patients were given glucose 100 g dissolved in water 200 ml. Blood samples were taken from the antecubital vein before and 10, 30, 60, 90, 120, 150 and 180 min after ingestion of the glucose. The patients then took chlorpromazine 75 mg/day for 7 days and the study was repeated immediately after discontinuation of the treatment.
During treatment with chlorpromazine (CPZ) a rise in blood glucose concentration has been reported (Hiles, 1956; Waitzkin, 1966; Gerich, Martin and Recant, 1971) . It has recently been observed that CPZ inhibits glucose-induced insulin secretion from Langerhans' islets in vitro (Ammon and Steinke, 1971; Ammon, Orci and Steinke, 1973 An intravenous glucose tolerance test was performed in ten subjects. The patients were given glucose 20 g in 3 rain. Blood samples were taken before and 3, 10, 20, 30, 35, 40, 45, 50 and 60 min after the glucose injection. Afterwards the patients were given chlorpromazine 50 mg/day for 7 days. A second IVGTT was done immediately after discontinuation of the CPZ treatment.
c. Experiment 3
Ten subjects received a CPZ infusion. The patients were recumbent during the study. Chlorpromazine 50 mg was dissolved in saline 250 ml and was infused over 60 min. Blood samples were taken 15 and 0 rain before and 30, 60, 90 and 120 min after starting the infusion.
d. Experiment 4
A first intravenous glucose tolerance test was done in 6 patients with chemical diabetes. 30 min before the glucose injection a saline infusion was begun which was continued until 30 rain after the glucose administration.
A few days later a second IVGTT was done and on this occasion, 30 rain before the glucose injection, a CPZ infusion was begun (50 mg in 60 min), which was continued until 30 rain after the glucose administration.
Blood samples were taken before the saline or CPZ infusion, 30 and 15 rain before the glucose injection and 3, 10, 20, 25, 30, 35, 40, 50, 60 and 90 min after the glucose administration.
The plasma insulin/blood glucose ratio was calculated by dividing the plasma level of glucose (mg/ 100 ml) by that of insulin (~tU/ml).
Before and during the experiments all the subjects were given a mixed diet containing at least 250 g of carbohydrates.
Blood glucose was measured by the method of Hugget and Nixon (1957) and plasma insulin according to Herbert (1967) .
Statistical Methods
In Experiments 1, 2 and 3 the statistical significance of the observed results was analyzed using paired comparisons (Student's 't' test).
In Experiment 4 the insulin/glucose ratios after i v glucose were analyzed by covariance analysis. basal glucose utilization rate was 1.78 + 0.09 and after treatment it was 1.76 + 0.18. There is no significant difference between these two results. The insulin response after glucose i. v. did not appear to be modified by administration of CPZ (Table 2) . Chlorpromazine infusion caused a slight but significant increase in blood glucose which was still evident 30 min after the end of the infusion (Fig. 1) . On the other hand, plasma insulin did not change during the infusion and after it the mean plasma insulin was slightly increased, but not significantly so. The insulin/ glucose ratio dropped slightly but not significantly during the infusion, but after it the ratio was significantly increased (Fig. 2) .
In patients with chemical diabetes, i. v. glucose injection during a CPZ infusion induced higher blood glucose levels and lower plasma insulin concentrations than in control tests, but the various differences at particular time did not appear to be significant (Table  3) . On the contrary, the differences between the insulin/glucose ratios during saline and CPZ infusions, after an i. v. glucose load, were statistically significant (p < 0.01).
Results Discussion
Daily administration of CPZ for 7 days in doses of 50 and 75 mg/day did not significantly modify basal levels of blood glucose or plasma insulin. After an oral glucose load, blood glucose levels observed after short-term CPZ treatment were slightly lower than those measured under basal conditions, but the difference was not statistically significant. The plasma insulin response induced by oral glucose showed no significant change after administration of CPZ (Table 1) . After intravenous injection of glucose, the mean
In the past few years it has been demonstrated repeatedly that CPZ produces hyperglycaemia and glucose intolerance in laboratory animals and in man (Hiles, 1956; Bhide, Tiwari and Balwani, 1965; Waitzkin, 1966; Mennear and Miya, 1970) . Recently Ammon et al. (1973) have shown that this drug inhibits insulin release from isolated islets of Langerhans in vivo and diminishes insulin secretion in rats. They suggested that the inhibition of insulin release was due to decreased activity in the beta-cells of Blood glucose  68  217  179  143  136  122  104  98  92  86  mg/100 ml  _+4  _+10  _+6  _+8  _+10  _+10  _+8  -+7  _+7  -+7  Plasma insulin  6  43  25  20  -19  -15  -15  ~tU/ml  _+2  -+7  _+3  _+3  -_+3  -_+3  -_+3   After CPZ treatment   Blood glucose  68  204  182  152  132  129  117  111  102  94  mg/100 ml  _+4  _+7  _+6  _+7  _+6  _+7  _+7  _+7  _+5  _+7  Plasma insulin  8  48  29  25  -22  -20  -17  ~U/ml  _+1  +7  -+5  -+4  -_+3  --+3  -_+3   Table 3 . Effect of CPZ infusion on blood glucose and plasma insulin before and after intravenous glucose injection in six subjects with chemical diabetes (Mean _+ SEM) Orci et al. (1972) have also reported that CPZ in small doses inhibited emiocytosis, whereas in high doses it increased the number of autophagosomes in pancreatic beta-cells. The present results show that at the dose employed for short-term treatment CPZ was ineffective in inhibiting basal and glucose-stimulated insulin secretion and that it did not impair oral or intravenous glucose tolerance. Also, and in agreement with the results obtained in dogs by Bhide et al. (1965) , shortterm treatment with CPZ did not affect peripheral glucose utilization in normal man.
Acute administration of CPZ increased the blood glucose level in normal man slightly but significantly, both during and after the infusion. This result was in accordance with observations by several investigators (Norman and Hiestand, 1955; Mennear et al., 1970; Ammon et al., 1973) . Since CPZ-induced hyperglycaemia did not increase plasma insulin levels, it is conceivable that acute administration of the drug might inhibit insulin release from pancreatic beta-cells in normal man. This hypothesis is supported by the significant increase in the insulin/glucose ratio after CPZ infusion.
In patients with chemical diabetes, CPZ infusion caused a significant fall in the insulin/glucose ratio after an intravenous glucose load. This result, too, was in agreement with the concept that CPZ inhibits insulin secretion in man.
Many investigators have demonstrated that CPZ may release catecholamines from the adrenals (Carlson and Hillarp, 1961; Opitz, 1962) and it has been suggested that the hyperglycaemic response to a single dose of CPZ alone is due, at least in part, to stimulation of the adrenals (Bhide et al., 1965; Mennear et al., 1970) . Indeed, in some of our patients CPZ infusion caused discomfort, tachycardia and slight hypotension. Therefore the present results cannot exclude the possibility that both the hyperglycaemia and inhibition of insulin release might have been due to increased release of catecholamines.
